Abstract 436P
Background
Robotic Endoscopic Submucosal Dissection (ESD) for Early-Stage Gastric Neoplasia represents a cutting-edge minimally invasive technique for the precise removal of early-stage gastric tumors. Traditionally, endoscopic resection has been limited by technical challenges and the risk of adverse events such as perforation. However, robotic ESD utilizes advanced robotic technology to enhance dexterity and visualization, enabling more precise dissection of lesions within the gastric submucosal layer. This innovative approach offers the potential for complete resection of neoplastic lesions with improved safety and efficacy, thus reducing the need for invasive surgical interventions and improving patient outcomes.
Methods
A systematic review and meta analysis was done by searching in Cochrane Central Register of Controlled Trials (CENTRAL), PubMed, MEDLINE (including MEDLINE InProcess) (OvidSP), Web of Science, Embase (OvidSP), and Scopus databases. ROB2 Cochrane tools assessment for RCTs. In the analysis, we used RevMan Cochrane software.
Results
5 studies were included; they were either cross sectional studies or retrospective studies. The total number of patients were 909 participants (males and females). Heterogeneity for the Progression-Free survival: Tau2 = 0.00; Chi2 = 5.35, df = 5 (P = 0.37); I2 = 7% and Test for overall effect: Z = 3.45 (P = 0.0006). Heterogeneity for overall survival rate: Tau2 = 0.00; Chi2 = 4.58, df = 5 (P = 0.47); I2 = 0% and Test for overall effect: Z = 5.95 (P < 0.00001).
Conclusions
Robotic endoscopic submucosal dissection represents a groundbreaking advancement in the management of early-stage gastric neoplasia. With its precision, dexterity, and enhanced visualization capabilities, this innovative technique offers a minimally invasive alternative to traditional surgical approaches. By enabling complete resection of lesions while minimizing risk and preserving gastric function, robotic endoscopic submucosal dissection holds great promise for improving patient outcomes and quality of life. As ongoing research continues to refine and validate its efficacy, this transformative technology is poised to become a cornerstone in the armamentarium against gastric neoplasia.
Legal entity responsible for the study
H.T. Hashim.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.